
    
      The objective of this study is to evaluate the efficacy and safety of ustekinumab, an
      interleukin (IL)-12/23 inhibitor, in patients with GCA

      Hypothesis IL-12/23 pathway blockade may maintain disease remission in patients with GCA

      Specific Aims

        -  To evaluate the safety and tolerability of ustekinumab administration in 20 patients
           with GCA

        -  To evaluate the efficacy of ustekinumab for remission maintenance and glucocorticoid
           sparing in 20 patients with GCA
    
  